IL100612A - History of 1-Araliphic acid-4-Hydroxy-2,8-Deoxavicilco-] 3, 2,1 [Octane 3,4,5- Tricarboxylic preparation and pharmaceutical preparations containing or - Google Patents

History of 1-Araliphic acid-4-Hydroxy-2,8-Deoxavicilco-] 3, 2,1 [Octane 3,4,5- Tricarboxylic preparation and pharmaceutical preparations containing or

Info

Publication number
IL100612A
IL100612A IL10061292A IL10061292A IL100612A IL 100612 A IL100612 A IL 100612A IL 10061292 A IL10061292 A IL 10061292A IL 10061292 A IL10061292 A IL 10061292A IL 100612 A IL100612 A IL 100612A
Authority
IL
Israel
Prior art keywords
group
ethyl acetate
water
formula
compounds
Prior art date
Application number
IL10061292A
Other languages
English (en)
Hebrew (he)
Other versions
IL100612A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100429A external-priority patent/GB9100429D0/en
Priority claimed from GB919100430A external-priority patent/GB9100430D0/en
Priority claimed from GB919100418A external-priority patent/GB9100418D0/en
Priority claimed from GB919100428A external-priority patent/GB9100428D0/en
Priority claimed from GB919116600A external-priority patent/GB9116600D0/en
Priority claimed from GB919116688A external-priority patent/GB9116688D0/en
Priority claimed from GB919117109A external-priority patent/GB9117109D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL100612A0 publication Critical patent/IL100612A0/xx
Publication of IL100612A publication Critical patent/IL100612A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10061292A 1991-01-09 1992-01-08 History of 1-Araliphic acid-4-Hydroxy-2,8-Deoxavicilco-] 3, 2,1 [Octane 3,4,5- Tricarboxylic preparation and pharmaceutical preparations containing or IL100612A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB919100429A GB9100429D0 (en) 1991-01-09 1991-01-09 Chemical compounds
GB919100430A GB9100430D0 (en) 1991-01-09 1991-01-09 Chemical compounds
GB919100418A GB9100418D0 (en) 1991-01-09 1991-01-09 Chemical compounds
GB919100428A GB9100428D0 (en) 1991-01-09 1991-01-09 Chemical compounds
GB919116600A GB9116600D0 (en) 1991-08-01 1991-08-01 Chemical compounds
GB919116688A GB9116688D0 (en) 1991-08-02 1991-08-02 Chemical compounds
GB919117109A GB9117109D0 (en) 1991-08-07 1991-08-07 Chemical compounds

Publications (2)

Publication Number Publication Date
IL100612A0 IL100612A0 (en) 1992-09-06
IL100612A true IL100612A (en) 1996-03-31

Family

ID=27562848

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10061292A IL100612A (en) 1991-01-09 1992-01-08 History of 1-Araliphic acid-4-Hydroxy-2,8-Deoxavicilco-] 3, 2,1 [Octane 3,4,5- Tricarboxylic preparation and pharmaceutical preparations containing or

Country Status (10)

Country Link
EP (2) EP0569386B1 (xx)
JP (1) JPH06504774A (xx)
AT (1) ATE143369T1 (xx)
AU (1) AU661469B2 (xx)
CA (1) CA2100257A1 (xx)
DE (1) DE69214127T2 (xx)
IE (1) IE920056A1 (xx)
IL (1) IL100612A (xx)
NZ (1) NZ241254A (xx)
WO (1) WO1992012159A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239663A (en) * 1990-09-13 1993-07-27 Merck & Co Inc Ester derivatives of dioxabicyclo(3,2,1)-octane, medicaments, and a fungus which makes them
US5506262A (en) * 1991-05-10 1996-04-09 Merck & Co., Inc. Cholesterol lowering compounds
US5256689A (en) * 1991-05-10 1993-10-26 Merck & Co., Inc. Cholesterol lowering compounds
WO1993003038A1 (en) * 1991-08-07 1993-02-18 Merck & Co., Inc. Novel cholesterol lowering compound
US5262435A (en) * 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5294627A (en) * 1992-08-27 1994-03-15 Merck & Co., Inc. Directed biosynthesis of biologically active compounds
US5302604A (en) * 1992-03-09 1994-04-12 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
GB9205140D0 (en) * 1992-03-10 1992-04-22 Glaxo Group Ltd Chemical compounds
GB9205136D0 (en) * 1992-03-10 1992-04-22 Glaxo Group Ltd Chemical compounds
US5258401A (en) * 1992-07-10 1993-11-02 Merck & Co., Inc. Cholesterol lowering compounds
US5369125A (en) * 1992-07-17 1994-11-29 Merck & Co., Inc. Cholesterol-lowering agents
US5283256A (en) * 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
US5270332A (en) * 1992-08-21 1993-12-14 Merck & Co., Inc. Cholesteral lowering agents
US5326783A (en) * 1992-08-25 1994-07-05 Merck & Co., Inc. Cholesterol lowering compounds
US5278320A (en) * 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
US5332728A (en) * 1992-11-23 1994-07-26 Bristol-Myers Squibb Company Method for treating a fungal infection
US5447717A (en) * 1993-02-25 1995-09-05 Merck & Co., Inc. Cholesterol-lowering agents
US5712261A (en) * 1993-10-04 1998-01-27 Magnin; David R. Method for preventing or treating hypertriglyceridemia
US5430055A (en) * 1994-04-08 1995-07-04 Pfizer Inc. Inhibitor of squalene synthase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH606071A5 (en) * 1972-05-30 1978-10-13 Ciba Geigy Ag Fibrinolytic anhydro-furanose ether derivs.
US4837205A (en) * 1986-09-02 1989-06-06 Merck & Co., Inc. Prodrugs of antihypercholesterolemic compounds
US5026554A (en) * 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
IL96440A (en) * 1990-11-22 1996-07-23 Shlomo Elfanbaum Method of using a play ladder
JPH06506912A (ja) * 1991-01-09 1994-08-04 グラクソ、グループ、リミテッド 環状ケタール誘導体
GB9105152D0 (en) * 1991-03-12 1991-04-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE69214127D1 (de) 1996-10-31
EP0497091A1 (en) 1992-08-05
EP0569386B1 (en) 1996-09-25
DE69214127T2 (de) 1997-02-13
JPH06504774A (ja) 1994-06-02
ATE143369T1 (de) 1996-10-15
WO1992012159A1 (en) 1992-07-23
IE920056A1 (en) 1992-07-15
IL100612A0 (en) 1992-09-06
AU661469B2 (en) 1995-07-27
EP0569386A1 (en) 1993-11-18
CA2100257A1 (en) 1992-07-10
NZ241254A (en) 1993-08-26
AU1156092A (en) 1992-08-17

Similar Documents

Publication Publication Date Title
EP0568546B1 (en) Bridged cyclic ketal derivatives
EP0569386B1 (en) Bridged cyclic ketal derivatives
KR100391401B1 (ko) 항진균성소르다리딘유도체
EP0494622A1 (en) Bridged cyclic ketal derivatives
WO1992016530A1 (en) Cyclic ketal derivatives
WO1992012158A1 (en) Cyclic ketal derivatives
WO1992012157A1 (en) Bridged cyclic ketal derivatives
WO1993018040A1 (en) Cyclic ketal derivatives
WO1993007151A1 (en) Cyclic ketal derivatives
WO1993002082A1 (en) Cyclic ketal derivatives
WO1993018039A1 (en) Cyclic ketal derivatives
WO1994022870A1 (en) Cyclic ketal derivatives for the treatment of acne

Legal Events

Date Code Title Description
HK Corrigendum

Free format text: IN JOURNAL NO. 1/96, PAGE 140, PATENT APPLICATION NO. 100612 CORRECT THE DATE OF THE APPLICATION TO8.1.1992.

FF Patent granted
KB Patent renewed
RH Patent void